Current reimbursement rules

Here are some examples of reimbursement rules for biosimilar drugs.

For more information, see the page Know the conditions for coverage This hyperlink will open in a new window. on the Régie de l'assurance maladie website.

Dermatology

Biosimilar drugs have been available in Canada since 2014.

  • Since 2020, all patients covered by RAMQ starting a new treatment must receive a biosimilar drug for:
    • Infliximab, whose reference product is RemicadeTM
    • Etanercept, whose reference product is EnbrelTM
  • Since March 2021, a new biosimilar drug has been available for adalimumab, and patients starting treatment receive this biosimilar drug, whose reference product is HumiraTM.

Endocrinology

Biosimilar drugs have been available in Canada since 2015.

  • Since 2017, all patients covered by RAMQ starting a new treatment must receive a biosimilar drug for insulin glargine, whose reference product is LantusTM.
  • Since March 2021, a new biosimilar drug has been available for insulin lispro. Patients starting treatment receive this biosimilar drug whose reference product is HumalogTM.

Gastroenterology

Biosimilar drugs have been available in Canada since 2014.

  • Since 2020, all patients covered by RAMQ starting a new treatment must receive a biosimilar drug for infliximab, whose reference product is RemicadeTM.
  • The biosimilar drug for adalimumab, whose reference drug is HumiraTM, has also been available since March 2021 and patients covered by RAMQ who are starting treatment now receive it.

Oncology

Biosimilar drugs have been available in Canada since 2019.

  • Since 2019, all patients treated in cancer centres in Québec starting a new treatment must receive a biosimilar drug for bevacizumab, whose reference product is AvastinTM.
  • Since 2020, a new biosimilar drug has been available for trastuzumab, and patients starting treatment receive this biosimilar drug whose reference product is HerceptinTM.

Neurology

Since 2018, all multiple sclerosis patients starting a new treatment receive glatiramer, whose reference product is CopaxoneTM. Note that glatiramer is not considered a biosimilar drug in the strict sense of the term, but a later complex non-biologic drug.

Rheumatology

Biosimilars have been available in Canada since 2016.

  • Since 2020, all patients covered by RAMQ starting a new treatment must receive a biosimilar drug for etanercept, whose reference product is EnbrelTM.
  • Since 2020, all patients covered by RAMQ starting a new treatment must receive a biosimilar drug for infliximab, whose reference product is RémicadeTM.
  • Since March 2021, a new biosimilar drug has been available for adalimumab. Patients starting treatment must receive this biosimilar drug, whose reference product is HumiraTM.

Biosimilar drugs in Québec

Table of biosimilar drugs covered by RAMQ and in facilities
Common nameName of the innovator or reference biologic drugBrand name of biosimilar drugs

Adalimumab

HumiraTM (AbbVie)

  • AmgevitaTM (Amgen)
  • HadlimaTM (Organon)
  • Hadlima PushTouchTM (Organon)
  • HulioTM (BGP Pharma)
  • HyrimozTM (Sandoz)
  • IdacioTM (Fresenius)

Bevacizumab

AvastinTM (Roche)

  • MvasiTM (Amgen)
  • ZirabevTM (Pfizer)

Étanercept

EnbrelTM (Amgen)

  • BrenzysTM (Organon)
  • ErelziTM (Sandoz)
  • Erelzi SensoReady PenTM (Sandoz)

Filgrastim

NeupogenTM

(Amgen)

  • GrastofilTM (Apotex)
  • NivestymTM (Pfizer)

Infliximab

RemicadeTM

(Janssen)

  • AvsolaTM (Amgen)
  • InflectraTM (Pfizer)
  • RenflexisTM (Organon)

Insulin glargine

LantusTM (Sanofi Aventis)

Lantus SolostarTM (Sanofi Aventis)

  • BasaglarTM(Lilly)
  • Basaglar KwikPenTM(Lilly)

Insulin lispro

HumalogTM

Humalog KwikPenTM

(Lilly)

  • AdmelogTM (Sanofi Aventis)
  • Admelog SoloStarTM 100 U/mL (Sanofi Aventis)

Pegfilgrastim

NeulastaTM

(Amgen)

  • FulphilaTM (BGP Pharma)
  • LapelgaTM (Apotex)
  • NyvepriaTM (Pfizer)
  • ZiextenzoTM (Sandoz)

Rituximab

RituxanMD

(Roche)

  • RiximyoTM (Sandoz)
  • RuxienceTM (Pfizer)
  • TruximaTM (Teva Innov)

Trastuzumab

HerceptinTM (Roche)

  • HerzumaTM (Teva Innov)
  • KanjintiTM (Amgen)
  • OgivriTM (BGP Pharma)
  • TrazimeraTM (Pfizer)
Table of later complex non-biologic drug covered by RAMQ and in facilities
Common nameBrand name of the innovator or reference biologic drugBrand name on the later complex non-biologic drug

Glatiramer

CopaxoneTM (Teva Innovation)

GlatectTM (Pharmascience)